Ricard N. Mesia
Badalona, CT 08916, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications
Baseline Nutritional Status and Early Treatment Response in Oropharyngeal Cancer: A Prospective Cohort Study by HPV Status (FIS 19 Study).
Journal: Nutrients
Published: May 22, 2026
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2026
An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
Journal: Oral oncology
Published: November 09, 2025
An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
Journal: Oral oncology
Published: November 09, 2025
Impact of clinical and dosimetric factors on severe oral mucositis in head and neck cancer: insights from a phase II clinical trial.
Journal: Frontiers in oncology
Published: August 04, 2025
A multiomic framework for predicting laryngo-esophageal dysfunction following induction chemotherapy in hypopharyngeal-laryngeal carcinoma.
Journal: ESMO open
Published: July 24, 2025
Clarifying the consensus on laryngeal preservation strategies - Authors' reply.
Journal: The Lancet. Oncology
Published: July 24, 2025
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: June 23, 2025
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Journal: ESMO open
Published: June 16, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.
Journal: Frontiers in oncology
Published: June 11, 2025
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.
Journal: Clinical and translational medicine
Published: May 20, 2025
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: Results in the pre-immunotherapy era.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 18, 2025
Last Updated: 09/26/2026